Inbox Robot - Choose newsletter content

Choose content

Enter keywords to create a newsletter

Create account

Enter your registration information

Set preferences

Set up your newsletter name, delivery and time zone preferences

Hint: Enter different keywords to generate new results.

Now you can:

Search the news index.
Browse more than 1 million newsletters by category.
Use preset newsletters:
- Quality of Health Care

Quality of Health Care Newsletter

Current Standard of Care and Treatment Options in Psoriasis 18 Nov 2025 20:01 GMT
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma 17 Nov 2025 11:43 GMT
… agent-of-choice and new standard of care in first-line HER2-positive …
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal… 17 Nov 2025 11:24 GMT
… Ziihera to become the new standard of care anti-HER2 therapy for patients … or without tislelizumab, to the standard of care (trastuzumab plus chemotherapy) as first … and one in combination with standard-of-care chemotherapy for first-line gastroesophageal …
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma 17 Nov 2025 11:00 GMT
… biotherapeutics to improve the standard of care for difficult-to-treat … zanidatamab to transform the standard of care in HER2+ indications, … one in combination with standard-of-care chemotherapy for first- … of-choice and new standard of care in first-line …
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma 17 Nov 2025 11:43 GMT
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of ZIIHERA and TEVIMBRA; zanidatamab- …
The Pope warns AI could erode the quality of healthcare. Is he right? 14 Nov 2025 05:57 GMT
After the Pope warned that artificial intelligence risks eroding personal bonds in healthcare, we asked experts for their thoughts – and heard how, in many cases, AI is already helping to strengthen them. AI has a “pervasive” influence on human life – …
<![CDATA[One-time TIL therapy shows durable responses in advanced lung cancer]]> 19 Nov 2025 23:34 GMT
… Germany, in the news release. Standard-of-care docetaxel in a similar patients …
AbbVie gets USFDA nod for Epkinly, Rituximab, Lenalidomide combo for Follicular Lymphoma 19 Nov 2025 22:30 GMT
… duration EPKINLY + R2 compared to standard of care R2 and demonstrates the potential … could potentially become a new standard of care." FL is typically an … <0.0001) compared to standard of care R2 alone. In the dual …
<![CDATA[FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer]]> 19 Nov 2025 22:07 GMT
… use of [Imdelltra] as a standard of care in second-line SCLC, including …
FDA Approves AbbVie’s EPKINLY Combination for Relapsed or Refractory Follicular Lymphoma 19 Nov 2025 20:14 GMT
… “could potentially become a new standard of care.” The safety profile of the …

Satisfied with the content?

Continue to create your account.

Choose content

Create account

Set preferences

EIN MARKETING SOLUTIONS

EIN NEWS SERVICES

ALL NEWS PUBLICATIONS